May 23 (UPI) --A panel of U.S. Food and Drug Administration advisers on Thursday recommended approval for a new blood test to detect colon and rectal cancer despite concerns over the test's accuracy.

Credit: Guardant. Guardant Health’s Shield blood test is a qualitative in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood. The Shield test is ...

Guardant Health’s blood test designed to help screen the population for hidden cases of colorectal cancer may have taken a step closer to FDA approval. An independent advisory panel convened by the ...

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health’s blood test to detect a cancer that begins in the colon or rectum. The panel voted ...